The FTC called out the nation’s leading pharmacy benefit managers for inflating pharmacy costs, affecting both employers and ...

FTC said the "Big 3 PBMs" — CVS’s Caremark, Cigna’s Express Scripts, and UnitedHealth’s OptumRx — imposed markups of hundreds to thousands of percent on critical drugs, including those for cancer and ...

A new FTC report found that pharmacy benefit managers have inflated the price of life-saving generic prescription drugs, ...

the Federal Trade Commission said in an interim report issued Tuesday. The practice came at a time when spending on drugs by patients, employers, insurers and others rose significantly. The nation’s ...

The FTC report found that from 2017 to 2022, three PBMs—UnitedHealth Group's Optum, CVS Health's CVS Caremark and Cigna's ...

The lawsuit claims that three major healthcare companies were pushing up the price of insulin by 1,200 percent.

The FTC’s findings—which analyzed 51 specialty generic drugs from 2017 to 2022—showed these pharmacy benefit managers’ (PBMs') affiliated pharmacies spun up $7.3 billion in excess revenue ...

The Federal Trade Commission has released a second report examining how ... in the Biden administration against the drug supply middlemen. The report accuses CVS’ Caremark, Cigna’s Express Scripts and ...

Oklahoma's attorney general has accused CVS's Caremark pharmacy benefit manager unit of under-reimbursing pharmacies for ...

The FTC analyzed data for 51 specialty generic drugs dispensed from 2017-2022 for patients with commercial insurance or Medicare Part D plans managed by CVS Caremark, Express Scripts and OptumRx.